Buy Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers
Book 1
Book 2
Book 3
Book 1
Book 2
Book 3
Book 1
Book 2
Book 3
Book 1
Book 2
Book 3
Home > Medicine & Health Science textbooks > Medical specialties, branches of medicine > Pharmacology > Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers: A Critical Analysis of Antihypertensive Strategies: A Machine-Generated Literature Overview
Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers: A Critical Analysis of Antihypertensive Strategies: A Machine-Generated Literature Overview

Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers: A Critical Analysis of Antihypertensive Strategies: A Machine-Generated Literature Overview


     0     
5
4
3
2
1



Out of Stock


Notify me when this book is in stock
X
About the Book

This book delves into the various aspects of the renin-angiotensin-aldosterone system (RAAS) and its role in cardiovascular disorders. It explores the use of anti-hypertensive agents, with a focus on (ACE) angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ARBs). The chapters cover topics such as the preferred use of ACE inhibitors over ARBs in high-risk patients, the impact of these agents on insulin resistance, their role in acute heart failure and peripheral artery disease, and their immunomodulatory activity in hypertensive patients. Additionally, the book examines the role of ACE inhibitors and ARBs in COVID-19 patients and provides insights into recent trends in managing hypertension through RAAS inhibition. It serves as a valuable resource for researchers, clinicians, and healthcare professionals involved in the field of cardiovascular medicine.

Table of Contents:
Chapter 1_ Introduction of the renin-angiotensin-aldosterone system (RAAS).- Chapter 2_ Role of anti-hypertensive agents in cardiovascular disorders.- Chapter 3_ (ACE) Angiotensin-converting enzyme inhibitors: Preferred RAAS inhibitor in high-risk patients as compared to angiotensin receptor blockers (ARBs).- Chapter 4_ Role of (ACE) angiotensin-converting enzyme inhibitors in transforming renin–angiotensin system.- Chapter 5_ The effect of (ACE) Angiotensin-converting enzyme inhibitors vs angiotensin receptor blockers on insulin resistance in hypertensive patients.- Chapter 6_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in acute heart failure.- Chapter 7_ Immunomodulator activity of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients.- Chapter 8_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peripheral artery disease.- Chapter 9_ Role of (ACE) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in covid-19 patients.- Chapter 10_ Recent trends in the management of hypertension through RAAS inhibition.

About the Author :
Dr. Mukesh Nandave is an In-charge Director of the School of Pharmaceutical Sciences, Associate Dean (Research), and head of the Department of Pharmacology and Pharmaceutical Biotechnology at Delhi Pharmaceutical Sciences and Research University, Govt. of NCT of Delhi, New Delhi, India. He has earlier served as associate professor and head of the Department of Pharmacology at NMIMS University, Mumbai (2010-2017). He has also worked as a research scientist in the Medical Affairs and Clinical Research Department of Ranbaxy Research Laboratories (currently known as Sun Pharmaceutical Industries Limited, Gurugram). Dr. Nandave earned his Ph. D. in pharmacology from AIIMS, Delhi and received his post-doctoral training from the Division of Cardiothoracic Surgery, the Ohio State University Medical Center, Columbus, USA. For more than 20 years, Dr. Nandave has investigated the role of nutraceuticals, herbomineral formulations, and phytoconstituents for myocardial ischemia & reperfusion injury, diabetes, obesity, and pain management. His lab received more than 3.5 crore total funding from Govt. (DBT, DST, ICMR, and AYUSH) as well as industry (Pharmazz, Dabur, Fertis India, Charak Pharma, Madhavbaug, and Sandu Pharma). He has published over 100 papers in peer-reviewed national and international journals, books, and book chapters. Dr. Nandave has received numerous awards including the Distinguished Leadership Award of International Academy of Cardiovascular Sciences; Prof. S. C. Lahiri Oration and G. Achari Gold Medal by Indian Pharmacological Society; Association of Pharmaceutical Teachers of India (APTI) Young Pharmacy Teacher of the Year Award, Early Investigator Award by International Society for Heart Research, Prof. Duggirala Visweswaram & Prof. Sreemantula Satyanarayana Prize; Best Research Output of the Year for 2014-2015, 2013-2014, and 2012-2013 Award" of SVKM's NMIMS University. Dr. Nandave is secretary general, of the International Academy of Cardiovascular Sciences (IACS)-India section and treasurer of the Society for Promotion and Research of Cardiovascular Sciences (SPARCS). He is a life member of various professional bodies including the International Society for Heart Research (ISHR), the International Academy of Cardiovascular Sciences (IACS); the Indian Pharmacological Society (IPS); the Indian Pharmaceutical Association (IPA); the Association of Physiologist and Pharmacologist of India (APPI); Association of Pharmaceutical Teachers of India (APTI); and Society for Ethnopharmacology.


Best Sellers


Product Details
  • ISBN-13: 9789819773824
  • Publisher: Springer Verlag, Singapore
  • Publisher Imprint: Springer Verlag, Singapore
  • Height: 235 mm
  • No of Pages: 602
  • Returnable: N
  • Returnable: N
  • Returnable: N
  • Returnable: N
  • Sub Title: A Critical Analysis of Antihypertensive Strategies: A Machine-Generated Literature Overview
  • ISBN-10: 9819773822
  • Publisher Date: 27 Oct 2025
  • Binding: Paperback
  • Language: English
  • Returnable: N
  • Returnable: N
  • Returnable: N
  • Returnable: N
  • Returnable: N
  • Width: 155 mm


Similar Products

Add Photo
Add Photo

Customer Reviews

REVIEWS      0     
Click Here To Be The First to Review this Product
Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers: A Critical Analysis of Antihypertensive Strategies: A Machine-Generated Literature Overview
Springer Verlag, Singapore -
Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers: A Critical Analysis of Antihypertensive Strategies: A Machine-Generated Literature Overview
Writing guidlines
We want to publish your review, so please:
  • keep your review on the product. Review's that defame author's character will be rejected.
  • Keep your review focused on the product.
  • Avoid writing about customer service. contact us instead if you have issue requiring immediate attention.
  • Refrain from mentioning competitors or the specific price you paid for the product.
  • Do not include any personally identifiable information, such as full names.

Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers: A Critical Analysis of Antihypertensive Strategies: A Machine-Generated Literature Overview

Required fields are marked with *

Review Title*
Review
    Add Photo Add up to 6 photos
    Would you recommend this product to a friend?
    Tag this Book Read more
    Does your review contain spoilers?
    What type of reader best describes you?
    I agree to the terms & conditions
    You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.

    CUSTOMER RATINGS AND REVIEWS AND QUESTIONS AND ANSWERS TERMS OF USE

    These Terms of Use govern your conduct associated with the Customer Ratings and Reviews and/or Questions and Answers service offered by Bookswagon (the "CRR Service").


    By submitting any content to Bookswagon, you guarantee that:
    • You are the sole author and owner of the intellectual property rights in the content;
    • All "moral rights" that you may have in such content have been voluntarily waived by you;
    • All content that you post is accurate;
    • You are at least 13 years old;
    • Use of the content you supply does not violate these Terms of Use and will not cause injury to any person or entity.
    You further agree that you may not submit any content:
    • That is known by you to be false, inaccurate or misleading;
    • That infringes any third party's copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy;
    • That violates any law, statute, ordinance or regulation (including, but not limited to, those governing, consumer protection, unfair competition, anti-discrimination or false advertising);
    • That is, or may reasonably be considered to be, defamatory, libelous, hateful, racially or religiously biased or offensive, unlawfully threatening or unlawfully harassing to any individual, partnership or corporation;
    • For which you were compensated or granted any consideration by any unapproved third party;
    • That includes any information that references other websites, addresses, email addresses, contact information or phone numbers;
    • That contains any computer viruses, worms or other potentially damaging computer programs or files.
    You agree to indemnify and hold Bookswagon (and its officers, directors, agents, subsidiaries, joint ventures, employees and third-party service providers, including but not limited to Bazaarvoice, Inc.), harmless from all claims, demands, and damages (actual and consequential) of every kind and nature, known and unknown including reasonable attorneys' fees, arising out of a breach of your representations and warranties set forth above, or your violation of any law or the rights of a third party.


    For any content that you submit, you grant Bookswagon a perpetual, irrevocable, royalty-free, transferable right and license to use, copy, modify, delete in its entirety, adapt, publish, translate, create derivative works from and/or sell, transfer, and/or distribute such content and/or incorporate such content into any form, medium or technology throughout the world without compensation to you. Additionally,  Bookswagon may transfer or share any personal information that you submit with its third-party service providers, including but not limited to Bazaarvoice, Inc. in accordance with  Privacy Policy


    All content that you submit may be used at Bookswagon's sole discretion. Bookswagon reserves the right to change, condense, withhold publication, remove or delete any content on Bookswagon's website that Bookswagon deems, in its sole discretion, to violate the content guidelines or any other provision of these Terms of Use.  Bookswagon does not guarantee that you will have any recourse through Bookswagon to edit or delete any content you have submitted. Ratings and written comments are generally posted within two to four business days. However, Bookswagon reserves the right to remove or to refuse to post any submission to the extent authorized by law. You acknowledge that you, not Bookswagon, are responsible for the contents of your submission. None of the content that you submit shall be subject to any obligation of confidence on the part of Bookswagon, its agents, subsidiaries, affiliates, partners or third party service providers (including but not limited to Bazaarvoice, Inc.)and their respective directors, officers and employees.

    Accept

    Fresh on the Shelf


    Inspired by your browsing history


    Your review has been submitted!

    You've already reviewed this product!